NCT07062978View on ClinicalTrials.gov

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

PHASE3RecruitingINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Postmenopausal Women With Osteoporosis at High Risk of Fracture
Interventions
DRUG

QL1206

QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

DRUG

Prolia®

Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Provincial People's Hospital Bijie Hospital, Guizhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY